SCS Capital Management LLC Decreases Stock Holdings in Alto Neuroscience, Inc. $ANRO

SCS Capital Management LLC lessened its holdings in Alto Neuroscience, Inc. (NYSE:ANRO) by 50.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,389 shares of the company’s stock after selling 33,388 shares during the period. SCS Capital Management LLC owned 0.11% of Alto Neuroscience worth $594,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. AdvisorShares Investments LLC purchased a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $785,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Alto Neuroscience by 14,567.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after purchasing an additional 211,222 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Alto Neuroscience by 20.8% in the fourth quarter. Geode Capital Management LLC now owns 287,435 shares of the company’s stock valued at $5,118,000 after purchasing an additional 49,535 shares in the last quarter. AlphaCore Capital LLC lifted its holdings in shares of Alto Neuroscience by 100.0% in the fourth quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $356,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Torren Management LLC purchased a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $62,000.

Alto Neuroscience Stock Performance

Shares of ANRO opened at $18.76 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 20.52 and a current ratio of 20.52. The company has a market capitalization of $658.15 million, a price-to-earnings ratio of -7.75 and a beta of 1.22. The company’s 50 day simple moving average is $22.94 and its 200 day simple moving average is $19.16. Alto Neuroscience, Inc. has a 1 year low of $2.15 and a 1 year high of $28.44.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, sell-side analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. JonesTrading reduced their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Bank of America assumed coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target on the stock. Wolfe Research assumed coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Alto Neuroscience in a report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and an average target price of $35.25.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.